 "medicine, drug, drugs, tablets")
Shares of Sun Pharma Advanced Research Company (SPARC) slipped 10 per cent to Rs 172 on the BSE on Wednesday in an otherwise strong market after the US health regulator rejected the cancer drug application.
SPARC on Tuesday said the company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.
Abraxane is indicated
SPARC on Tuesday said the company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.
Abraxane is indicated
